Extended Data Fig. 1: Estimated prevalence of the CTNNB1S37F mutation.
From: TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors
a, Number of unique patient tumor samples in the different cancer types analyzed in the MSK-MET study23. b, Mutation prevalence by cancer type, estimated from cancer specimens reported in the MSK-MET study23. For each cancer type and group, the prevalence is displayed as percentage, with the number of CTNNB1S37F-mutated samples among the total the number of samples analyzed in brackets. In a and b, blue = metastatic cases, orange = primary cases.
